- AU$98.98m
- AU$70.83m
- AU$79.51m
- 94
- 82
- 54
- 88
Annual balance sheet for Vita Life Sciences, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 14.5 | 15.9 | 15.7 | 24.6 | 28.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6.94 | 7.12 | 8.98 | 11.2 | 12 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 29.2 | 35.1 | 41.2 | 48.3 | 58.9 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 8.37 | 8.26 | 8.47 | 9.17 | 10.3 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 39.1 | 45.3 | 51.8 | 59.8 | 71.9 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 13 | 14.5 | 14.9 | 16.2 | 19.3 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 14.4 | 14.5 | 15.2 | 16.4 | 19.5 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 24.7 | 30.8 | 36.6 | 43.4 | 52.4 |
| Total Liabilities & Shareholders' Equity | 39.1 | 45.3 | 51.8 | 59.8 | 71.9 |
| Total Common Shares Outstanding |